Quantcast
Last updated on April 16, 2014 at 17:25 EDT

Latest Gynecologic oncology Stories

2013-01-31 04:21:35

SEATTLE, Jan. 31, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that the Gynecologic Oncology Group (GOG) informed CTI that an independent Data Safety Monitoring Board (DSMB) recommended continuation of the GOG-0212 Phase 3 clinical trial of OPAXIO(TM )(paclitaxel poliglumex) as maintenance therapy in ovarian cancer with no changes following a planned interim survival analysis. CTI remains blinded to the interim analysis results. GOG-0212...

2012-12-06 05:04:24

Fellowship trained in treating cancers of the female reproductive system, Burton's expertise further enhances the wide range of Gyn Oncology services available at Abington Memorial Hospital. Abington, PA (PRWEB) December 06, 2012 Gynecologic Oncologist Elizabeth R. Burton, M.D., recently joined the staff of Abington Memorial Hospital´s Hanjani Institute for Gynecologic Oncology. Burton earned a Bachelor of Arts degree from Bowdoin College where she made the dean´s list for four...

2012-11-28 12:26:30

AUSTIN, Texas, Nov. 28, 2012 /PRNewswire/ -- Gynecologic Oncology, the prestigious medical journal of the Society for Gynecologic Oncology, has published the second prospective clinical study of OVA1® which demonstrated the positive performance of the multi-biomarker test in the triage of early-stage ovarian cancer. Vermillion, Inc. (NASDAQ: VRML), the molecular diagnostics company which developed and currently markets the test, had reported positive top-line results of the study in...

2012-11-21 16:21:58

Dr. Jamal Rahaman, a Board Certified New York, NY physician specializing in Gynecologic Oncology, has been selected by Castle Connolly Medical Ltd. for inclusion in its authoritative guide to the top primary care and specialty care doctors in the tri-state metropolitan New York area. NEW YORK, Nov. 21, 2012 /PRNewswire-USNewswire/ -- Castle Connolly Medical Ltd., America's trusted source for identifying Top Doctors, has published the 15th edition of Top Doctors: New York Metro Area and...

2012-07-30 02:26:03

AUSTIN, Texas, July 30, 2012 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a leading molecular diagnostics company, today announced positive results from a new prospective, multi-center clinical study of its ovarian cancer diagnostic OVA1®. The study, referred to as OVA500, was led by Dr. Robert E. Bristow, director of Gynecologic Oncology Services at UC Irvine Healthcare in Orange, CA, and deputy editor of the journal Gynecologic Oncology. OVA1 is a blood test for pre-surgical...

2012-06-20 10:23:00

"Sandwiched" Sequencing of Chemotherapy and Radiation Resulted in More Than 80% Survival Rates in Early Stage Patients NEW YORK, June 20, 2012 /PRNewswire-USNewswire/ -- "Sandwich" therapy that uses chemotherapy and radiation treatment in sequence has been found to be extremely effective in treating aggressive forms of uterine cancer, according to two concurrent Montefiore Medical Center studies. These studies support that the combination therapy delivered in a "sandwich" fashion is...

2012-06-01 02:24:18

CLEVELAND, June 1, 2012 /PRNewswire/ -- In a Phase 2 study presented at the 48th Annual Meeting of the American Society for Clinical Oncology (ASCO), clinical researchers from University Hospitals Case Medical Center's Seidman Cancer Center developed a more effective way to treat gynecologic cancers, shortening radiation treatment time from five weeks to three days. The new method, stereotactic body radiotherapy (SBRT), has been used on other types of cancer, but University Hospitals Case...

2012-05-08 20:55:55

White and affluent women did better than African American and poor women Poor women and African Americans with ovarian cancer are less likely to receive the highest standards of care, leading to worse outcomes than among white and affluent patients, according to a study of 50,000 women presented by UC Irvine´s Dr. Robert Bristow at the Society of Gynecologic Oncology´s annual meeting March 27. “Not all women are benefiting equally from improvements in ovarian cancer...

2012-04-03 06:26:00

CHICAGO, April 3, 2012 /PRNewswire-USNewswire/ -- Ronald D. Alvarez, MD, Professor and Director of the Division of Gynecologic Oncology at the University of Alabama at Birmingham (UAB), has been elected the 44th President of the Society of Gynecologic Oncology (SGO) at its 43rd Annual Meeting on Women's Cancer held March 24-27, 2012, in Austin, TX. "We are in the midst of evolutionary times and our members need to be prepared for the changes coming with health care reform," states Dr....

2012-03-27 06:24:11

AUSTIN, Texas, March 27, 2012 /PRNewswire-USNewswire/ -- Today at the Society of Gynecologic Oncology (SGO) 43rd Annual Meeting on Women's Cancer®, Dr. Jonathan Ledermann, Director of Cancer Services and Professor of Medical Oncology at University College London, presented new data updating the overall survival of women enrolled in a "Phase II randomized placebo-controlled study of olaparib (AZD2281) maintenance in patients with platinum-sensitive relapsed serous ovarian cancer." This...